258 related articles for article (PubMed ID: 21205836)
1. EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells.
Taddei ML; Parri M; Angelucci A; Bianchini F; Marconi C; Giannoni E; Raugei G; Bologna M; Calorini L; Chiarugi P
Mol Cancer Res; 2011 Feb; 9(2):149-60. PubMed ID: 21205836
[TBL] [Abstract][Full Text] [Related]
2. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style.
Parri M; Taddei ML; Bianchini F; Calorini L; Chiarugi P
Cancer Res; 2009 Mar; 69(5):2072-81. PubMed ID: 19244130
[TBL] [Abstract][Full Text] [Related]
3. Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence.
Lin KT; Gong J; Li CF; Jang TH; Chen WL; Chen HJ; Wang LH
Cancer Res; 2012 Jun; 72(12):3000-9. PubMed ID: 22659453
[TBL] [Abstract][Full Text] [Related]
4. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.
Taddei ML; Parri M; Angelucci A; Onnis B; Bianchini F; Giannoni E; Raugei G; Calorini L; Rucci N; Teti A; Bologna M; Chiarugi P
Am J Pathol; 2009 Apr; 174(4):1492-503. PubMed ID: 19264906
[TBL] [Abstract][Full Text] [Related]
5. Loss of proline-rich tyrosine kinase 2 function induces spreading and motility of epithelial prostate cells.
de Amicis F; Lanzino M; Kisslinger A; Calì G; Chieffi P; Andò S; Mancini FP; Tramontano D
J Cell Physiol; 2006 Oct; 209(1):74-80. PubMed ID: 16783820
[TBL] [Abstract][Full Text] [Related]
6. The chemopreventive bioflavonoid apigenin inhibits prostate cancer cell motility through the focal adhesion kinase/Src signaling mechanism.
Franzen CA; Amargo E; Todorović V; Desai BV; Huda S; Mirzoeva S; Chiu K; Grzybowski BA; Chew TL; Green KJ; Pelling JC
Cancer Prev Res (Phila); 2009 Sep; 2(9):830-41. PubMed ID: 19737984
[TBL] [Abstract][Full Text] [Related]
7. Ectopical expression of human MUC18 increases metastasis of human prostate cancer cells.
Wu GJ; Peng Q; Fu P; Wang SW; Chiang CF; Dillehay DL; Wu MW
Gene; 2004 Mar; 327(2):201-13. PubMed ID: 14980717
[TBL] [Abstract][Full Text] [Related]
8. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells.
Nasreen N; Mohammed KA; Antony VB
Cancer; 2006 Nov; 107(10):2425-35. PubMed ID: 17041885
[TBL] [Abstract][Full Text] [Related]
9. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis.
Fang WB; Brantley-Sieders DM; Parker MA; Reith AD; Chen J
Oncogene; 2005 Nov; 24(53):7859-68. PubMed ID: 16103880
[TBL] [Abstract][Full Text] [Related]
10. Transfected neu oncogene induces human prostate cancer metastasis.
Zhau HY; Zhou J; Symmans WF; Chen BQ; Chang SM; Sikes RA; Chung LW
Prostate; 1996 Feb; 28(2):73-83. PubMed ID: 8604395
[TBL] [Abstract][Full Text] [Related]
11. Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts.
Kaminski A; Hahne JC; Haddouti el-M; Florin A; Wellmann A; Wernert N
Int J Mol Med; 2006 Nov; 18(5):941-50. PubMed ID: 17016625
[TBL] [Abstract][Full Text] [Related]
12. Cell adhesion and EGFR activation regulate EphA2 expression in cancer.
Larsen AB; Stockhausen MT; Poulsen HS
Cell Signal; 2010 Apr; 22(4):636-44. PubMed ID: 19948216
[TBL] [Abstract][Full Text] [Related]
13. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
14. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
[TBL] [Abstract][Full Text] [Related]
15. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
16. EphA2 induction of fibronectin creates a permissive microenvironment for malignant cells.
Hu M; Carles-Kinch KL; Zelinski DP; Kinch MS
Mol Cancer Res; 2004 Oct; 2(10):533-40. PubMed ID: 15498927
[TBL] [Abstract][Full Text] [Related]
17. Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance.
Monet M; Lehen'kyi V; Gackiere F; Firlej V; Vandenberghe M; Roudbaraki M; Gkika D; Pourtier A; Bidaux G; Slomianny C; Delcourt P; Rassendren F; Bergerat JP; Ceraline J; Cabon F; Humez S; Prevarskaya N
Cancer Res; 2010 Feb; 70(3):1225-35. PubMed ID: 20103638
[TBL] [Abstract][Full Text] [Related]
18. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.
Abraham S; Knapp DW; Cheng L; Snyder PW; Mittal SK; Bangari DS; Kinch M; Wu L; Dhariwal J; Mohammed SI
Clin Cancer Res; 2006 Jan; 12(2):353-60. PubMed ID: 16428472
[TBL] [Abstract][Full Text] [Related]
19. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
[TBL] [Abstract][Full Text] [Related]
20. Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer.
Kang HY; Huang HY; Hsieh CY; Li CF; Shyr CR; Tsai MY; Chang C; Chuang YC; Huang KE
J Bone Miner Res; 2009 Jul; 24(7):1180-93. PubMed ID: 19257827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]